Leerink Partners Initiates Coverage On Kailera Therapeutics with Outperform Rating, Announces Price Target of $36
Benzinga Newsdesk 5 months ago
NewsPrice TargetInitiationAnalyst Ratings
Leerink Partners analyst David Risinger initiates coverage on Kailera Therapeutics (NASDAQ:KLRA) with a Outperform rating and announces Price Target of $36.
Leerink Partners analyst David Risinger initiates coverage on Kailera Therapeutics (NASDAQ:KLRA) with a Outperform rating and announces Price Target of $36.